Evin, G., Sernee, M.F. & Masters, C.L. Inhibition of γ-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs 20, 351–372 (2006).
Selkoe, D. & Kopan, R. Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26, 565–597 (2003).
Weng, A.P. et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306, 269–271 (2004).
Roy, M., Pear, W.S. & Aster, J.C. The multifaceted role of Notch in cancer. Curr. Opin. Genet. Dev. 17, 52–59 (2007).
Deangelo, D. et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J. of Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. 24, 6585 (2006).
Palomero, T. et al. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors. Leukemia 20, 1279–1287 (2006).
Lewis, H.D. et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem. Biol. 14, 209–219 (2007).
Milano, J. et al. Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. 82, 341–358 (2004).
van Es, J.H. et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005).
Wong, G.T. et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279, 12876–12882 (2004).
Searfoss, G.H. et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional γ-secretase inhibitor. J. Biol. Chem. 278, 46107–46116 (2003).
Pear, W.S. & Radtke, F. Notch signaling in lymphopoiesis. Semin. Immunol. 15, 69–79 (2003).
Ciofani, M. & Zuniga-Pflucker, J.C. Notch promotes survival of pre-T cells at the β-selection checkpoint by regulating cellular metabolism. Nat. Immunol. 6, 881–888 (2005).
Deftos, M.L., He, Y.W., Ojala, E.W. & Bevan, M.J. Correlating Notch signaling with thymocyte maturation. Immunity 9, 777–786 (1998).
Aster, J.C., Pear, W.S. & Blacklow, S.C. Notch signaling in leukemia. Annu. Rev. Pathol. 3, 587–613 (2008).
Palomero, T., Dominguez, M. & Ferrando, A.A. The role of the PTEN/AKT pathway in NOTCH1-induced leukemia. Cell Cycle 7, 965–970 (2008).
Palomero, T. & Ferrando, A. Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T cell acute lymphoblastic leukemias and lymphomas. Clin. Cancer Res. 14, 5314–5317 (2008).
Seiffert, D. et al. Presenilin-1 and -2 are molecular targets for γ-secretase inhibitors. J. Biol. Chem. 275, 34086–34091 (2000).
Palomero, T. et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 103, 18261–18266 (2006).
Palomero, T. et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13, 1203–1210 (2007).
Eisen, L.P., Elsasser, M.S. & Harmon, J.M. Positive regulation of the glucocorticoid receptor in human T cells sensitive to the cytolytic effects of glucocorticoids. J. Biol. Chem. 263, 12044–12048 (1988).
Ramdas, J., Liu, W. & Harmon, J.M. Glucocorticoid-induced cell death requires autoinduction of glucocorticoid receptor expression in human leukemic T cells. Cancer Res. 59, 1378–1385 (1999).
Levine, E.G., Peterson, B.A., Smith, K.A., Hurd, D.D. & Bloomfield, C.D. Glucocorticoid receptors in chronic lymphocytic leukemia. Leuk. Res. 9, 993–999 (1985).
Leventhal, B.G. Glucocorticoid receptors in lymphoid tumors. Cancer Res. 41, 4861–4862 (1981).
Pedersen, K.B. & Vedeckis, W.V. Quantification and glucocorticoid regulation of glucocorticoid receptor transcripts in two human leukemic cell lines. Biochemistry 42, 10978–10990 (2003).
Pedersen, K.B., Geng, C.D. & Vedeckis, W.V. Three mechanisms are involved in glucocorticoid receptor autoregulation in a human T lymphoblast cell line. Biochemistry 43, 10851–10858 (2004).
Renner, K., Ausserlechner, M.J. & Kofler, R. A conceptual view on glucocorticoid-lnduced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Curr. Mol. Med. 3, 707–717 (2003).
Geley, S. et al. Resistance to glucocorticoid-induced apoptosis in human T cell acute lymphoblastic leukemia CEM-C1 cells is due to insufficient glucocorticoid receptor expression. Cancer Res. 56, 5033–5038 (1996).
Schmidt, S. et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J. 20, 2600–2602 (2006).
Breslin, M.B., Geng, C.D. & Vedeckis, W.V. Multiple promoters exist in the human GR gene, one of which is activated by glucocorticoids. Mol. Endocrinol. 15, 1381–1395 (2001).
Geng, C.D. & Vedeckis, W.V. c-Myb and members of the c-Ets family of transcription factors act as molecular switches to mediate opposite steroid regulation of the human glucocorticoid receptor 1A promoter. J. Biol. Chem. 280, 43264–43271 (2005).
Nunez, B.S. & Vedeckis, W.V. Characterization of promoter 1B in the human glucocorticoid receptor gene. Mol. Cell. Endocrinol. 189, 191–199 (2002).
Erlacher, M. et al. BH3-only proteins Puma and Bim are rate-limiting for γ-radiation– and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106, 4131–4138 (2005).
Abrams, M.T., Robertson, N.M., Yoon, K. & Wickstrom, E. Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA. J. Biol. Chem. 279, 55809–55817 (2004).
Wang, Z., Malone, M.H., He, H., McColl, K.S. & Distelhorst, C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J. Biol. Chem. 278, 23861–23867 (2003).
Puthalakath, H. et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293, 1829–1832 (2001).
Guo, K. et al. Disruption of peripheral leptin signaling in mice results in hyperleptinemia without associated metabolic abnormalities. Endocrinology 148, 3987–3997 (2007).
Katz, J.P. et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development 129, 2619–2628 (2002).
Wei, D., Kanai, M., Huang, S. & Xie, K. Emerging role of KLF4 in human gastrointestinal cancer. Carcinogenesis 27, 23–31 (2006).
Jensen, J. et al. Control of endodermal endocrine development by Hes-1. Nat. Genet. 24, 36–44 (2000).
Stappenbeck, T.S., Wong, M.H., Saam, J.R., Mysorekar, I.U. & Gordon, J.I. Notes from some crypt watchers: regulation of renewal in the mouse intestinal epithelium. Curr. Opin. Cell Biol. 10, 702–709 (1998).
Sicinski, P. et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384, 470–474 (1996).
Wei, G. et al. Gene expression–based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10, 331–342 (2006).
Jang, J. et al. Notch1 confers thymocytes a resistance to GC-induced apoptosis through Deltex1 by blocking the recruitment of p300 to the SRG3 promoter. Cell Death Differ. 13, 1495–1505 (2006).
Choi, Y.I. et al. Notch1 confers a resistance to glucocorticoid-induced apoptosis on developing thymocytes by down-regulating SRG3 expression. Proc. Natl. Acad. Sci. USA 98, 10267–10272 (2001).
Jeon, S.H. et al. A new mouse gene, SRG3, related to the SWI3 of Saccharomyces cerevisiae, is required for apoptosis induced by glucocorticoids in a thymoma cell line. J. Exp. Med. 185, 1827–1836 (1997).
Han, H. et al. Inducible gene knockout of transcription factor recombination signal binding protein-J reveals its essential role in T versus B lineage decision. Int. Immunol. 14, 637–645 (2002).